NCT07096752Not yet recruiting
Screening and Validation of Serum Protein Biomarkers for Early Diagnosis of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 31 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1200 (estimated)
- First submitted
- 23 Jul 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07096752
What you commit to
- Study type: Observational
- Planned participants: 1200
- From 1 Aug 2025 to the primary completion date, 31 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of concurrent malignancies of other types.
Other illness
- Patients meeting any of the following conditions will be excluded:
- History of prior malignancy or cancer treatment.
Other
- Inability to tolerate gastroscopy.
Who the study is looking for
- Gastric cancer patients enrolled in this study must meet all of the following criteria:
- Male or female, aged ≥18 and ≤95 years.
- Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer.
- No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
- Availability of complete clinicopathological data and follow-up information.
- Patients with precancerous gastric lesions must meet all of the following criteria:
- Male or female, aged ≥18 and ≤95 years.
- Histopathologically confirmed absence of gastric cancer.
- Diagnosis consistent with precancerous gastric lesions as defined by the American Society for Gastrointestinal Endoscopy (ASGE, 2015 edition).
- Availability of complete clinicopathological data and follow-up information.
- Healthy controls must meet all of the following criteria:
- Male or female, aged ≥18 and ≤95 years.
- Histopathologically confirmed absence of gastric cancer.
- No evidence of precancerous gastric lesions.
- Availability of complete clinicopathological data and follow-up information.
Age in the registry: 18 years to 95 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.